Tilray | TRLY - Net Income


Tilray reported $-44.93M in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
Acasti Pharma USD -938K 2.42M Sep/2025
Akebia Therapeutics USD -12.24M 12.78M Dec/2025
Alaunos Therapeutics USD -1.01M 153K Mar/2026
Aurora Cannabis CAD -71.1M 72.92M Mar/2026
Avita Medical AUD -11.62M 1.7M Dec/2025
Canopy Growth CAD -157.11M 94.49M Mar/2026
Cronos Group USD 32.08M 18.33M Jun/2026
Dianthus Therapeutics USD -40.83M 23.6M Mar/2026
Divis Laboratories Ltd INR 9.02B 1.51B Jun/2026
Ionis Pharmaceuticals USD -114.65M 21.65M Jun/2026
IQVIA Holdings USD 256M 18M Jun/2026
Knight Therapeutics CAD -3.79M 8.83M Sep/2025
Moderna USD -1.34B 517M Mar/2026
Organigram Holdings CAD -921K 20.89M Mar/2026
Organon & Co USD 108M 38M Jun/2026
Revvity USD 51.82M 11.1M Jun/2026
Tectonic Therapeutic USD -25.24M 6.02M Mar/2026
Tilray USD -44.93M 44.61M Sep/2025
Viatris USD -118.8M 295.2M Jun/2026
Xeris Pharmaceuticals USD 2.23M 8.85M Mar/2026
Zealand Pharma A/S -394M 14.88M Mar/2026